377 related articles for article (PubMed ID: 18286246)
1. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
Grassegger A; Pohla-Gubo G; Frauscher M; Hintner H
Wien Med Wochenschr; 2008; 158(1-2):19-28. PubMed ID: 18286246
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
Hamaguchi Y
J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of autoantibodies in scleroderma.
Ho KT; Reveille JD
Arthritis Res Ther; 2003; 5(2):80-93. PubMed ID: 12718748
[TBL] [Abstract][Full Text] [Related]
4. Antinuclear Antibodies in Systemic Sclerosis: an Update.
Stochmal A; Czuwara J; Trojanowska M; Rudnicka L
Clin Rev Allergy Immunol; 2020 Feb; 58(1):40-51. PubMed ID: 30607749
[TBL] [Abstract][Full Text] [Related]
5. [Assessment of serum IgG activity correlation against cyclic citrullinated peptide antibodies, topoisomerase I and centromere proteins in Mexican patients with progressive systemic sclerosis].
Rocha-Muñoz AD; González-López L; Peguero-Gómez R; Aguilar-Chávez EA; Villa-Manzano AI; Corona-Sánchez E; Galván-Méndez S; Presiado-Sánchez C; Vázquez-Jiménez JC; Riebeling C; Salazar-Páramo M; Gámez-Nava JI; Nava A
Rev Alerg Mex; 2009; 56(4):103-7. PubMed ID: 19768971
[TBL] [Abstract][Full Text] [Related]
6. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?
Diot E; Giraudeau B; Diot P; Degenne D; Ritz L; Guilmot JL; Lemarié E
Chest; 1999 Sep; 116(3):715-20. PubMed ID: 10492277
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic autoantibodies in systemic sclerosis.
Gabrielli A; Svegliati S; Moroncini G; Avvedimento EV
Curr Opin Immunol; 2007 Dec; 19(6):640-5. PubMed ID: 18083509
[TBL] [Abstract][Full Text] [Related]
8. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
[TBL] [Abstract][Full Text] [Related]
9. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
Patterson KA; Roberts-Thomson PJ; Lester S; Tan JA; Hakendorf P; Rischmueller M; Zochling J; Sahhar J; Nash P; Roddy J; Hill C; Nikpour M; Stevens W; Proudman SM; Walker JG
Arthritis Rheumatol; 2015 Dec; 67(12):3234-44. PubMed ID: 26246178
[TBL] [Abstract][Full Text] [Related]
10. [Systemic sclerosis autoantibodies: what dermatologists must know].
Hüe S; Ingen-Housz-Oro S; Cosnes A
Ann Dermatol Venereol; 2013 Feb; 140(2):143-9. PubMed ID: 23395500
[No Abstract] [Full Text] [Related]
11. Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma).
Reimer G
Rheum Dis Clin North Am; 1990 Feb; 16(1):169-83. PubMed ID: 2406806
[TBL] [Abstract][Full Text] [Related]
12. Late onset systemic sclerosis with seronegativity: a rare presentation of an uncommon disease.
Saxena D; Jain D; Yadav M; Giri K; Yadav T; Jain P
Reumatismo; 2019 Oct; 71(3):166-170. PubMed ID: 31649382
[TBL] [Abstract][Full Text] [Related]
13. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Ceribelli A; Krzyszczak ME; Li Y; Ross SJ; Chan JY; Chan EK; Burlingame RW; Webb TT; Bubb MR; Sobel ES; Reeves WH; Satoh M
Arthritis Res Ther; 2011 Jul; 13(4):R119. PubMed ID: 21781293
[TBL] [Abstract][Full Text] [Related]
14. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic relevance of autoantibodies in uranium miners.
Conrad K; Mehlhorn J
Int Arch Allergy Immunol; 2000 Sep; 123(1):77-91. PubMed ID: 11014974
[TBL] [Abstract][Full Text] [Related]
16. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis.
Bonroy C; Van Praet J; Smith V; Van Steendam K; Mimori T; Deschepper E; Deforce D; Devreese K; De Keyser F
J Immunol Methods; 2012 May; 379(1-2):53-60. PubMed ID: 22446156
[TBL] [Abstract][Full Text] [Related]
17. Serological profile of patients with systemic sclerosis.
Wielosz E; Dryglewska M; Majdan M
Postepy Hig Med Dosw (Online); 2014 Aug; 68():987-91. PubMed ID: 25228505
[TBL] [Abstract][Full Text] [Related]
18. Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients.
Brinckmann J; Hunzelmann N; El-Hallous E; Krieg T; Sakai LY; Krengel S; Reinhardt DP
Arthritis Res Ther; 2005; 7(6):R1221-6. PubMed ID: 16277674
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice.
Murai C; Saito S; Kasturi KN; Bona CA
Autoimmunity; 1998; 28(3):151-5. PubMed ID: 9867127
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
Heijnen IA; Foocharoen C; Bannert B; Carreira PE; Caporali R; Smith V; Kumánovics G; Becker MO; Vanthuyne M; Simsek I; Bocelli-Tyndall C; Walker UA
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):96-102. PubMed ID: 23101460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
